KITLG and gastrointestinal stromal tumor: Approximately 80% of GIST tumors harbor an identifiable gain-of-function KIT mutation, and more than half of driver mutations are located in exon 11 that encodes the juxtamembrane domain responsible for inhibiting receptor dimerization (activation) when the SCF ligand is absent (Shen et al., 2020).